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ABSTRACT We studied secretory phospholipase A2 type IIA (sPLA2) activity toward phospholipids that are derivatized in the
sn-1 position of the glycerol backbone. We explored what type of side group (small versus bulky groups, hydrophobic versus
polar groups) can be introduced at the sn-1 position of the glycerol backbone of glycerophospholipids and at the same time be
hydrolyzed by sPLA2. The biophysical characterization revealed that the modiﬁed phospholipids can form multilamellar
vesicles, and several of the synthesized sn-1 functionalized phospholipids were hydrolyzed by sPLA2. Molecular dynamics
simulations provided detailed insight on an atomic level that can explain the observed sPLA2 activity toward the different
phospholipid analogs. The simulations revealed that, depending on the nature of the side chain located at the sn-1 position, the
group may interfere with an incoming water molecule that acts as the nucleophile in the enzymatic reaction. The simulation
results are in agreement with the experimentally observed sPLA2 activity toward the different phospholipid analogs.
INTRODUCTION
Phospholipase A2 (PLA2; EC 3.1.1.4) comprises a diverse
superfamily of lipolytic enzymes that speciﬁcally cleave the
sn-2 acyl ester bond of glycerophospholipids to produce
free fatty acids and lysophospholipids (1–6). Over the past
two decades, numerous PLA2s have been identiﬁed and
characterized (7–9). According to their biochemical features,
such as cellular localization, requirement of Ca21, substrate
speciﬁcity, and primary structure, these PLA2s are classiﬁed
into several families, including low-molecular-weight secre-
tory PLA2 (sPLA2), Ca
21-sensitive arachidonoyl-speciﬁc
85-kDa cytosolic PLA2 (cPLA2), and Ca
21-independent
PLA2 (iPLA2). Secretory phospholipases are small enzymes
(14–19 kDa) that are classiﬁed into at least four subgroups
based on structural differences (10,11). They have several
features that distinguish them from other PLA2 families,
such as high-disulﬁde-bond content, a requirement for
millimolar concentration of Ca21 for catalysis, and a broad
speciﬁcity for phospholipids with different polar headgroups
and fatty acid chains (12). The activity of these lipolytic
enzymes increases substantially when adsorbed onto a lipid-
water interface (13–17)—a phenomenon known as interfacial
activation (18). However, there are dramatically different
afﬁnities of the various sPLA2s for membrane surfaces
containing different phospholipids (19,20). It has been
suggested that this afﬁnity is controlled by the difference
in the amino acids located on the interfacial binding surface
(interfacial speciﬁcity) rather than the substrate afﬁnity being
controlled by the active site residues (catalytic site speciﬁc-
ity) (21–23). The interfacial binding speciﬁcity of sPLA2s
has important physiological consequences. sPLA2 generally
prefers membranes containing anionic lipids (20,24). Human
sPLA2-IIA binds several orders of magnitude more tightly to
anionic phospholipid membranes than to a membrane
composed of zwitterionic (charge-neutral) phosphatidylcho-
line lipids (19,20,25). The speciﬁcity of the enzyme to-
ward anionic membranes is driven by electrostatic forces
(24,26,27), since the enzyme has a relatively large number of
cationic residues, resulting in an isoelectric point for the
enzyme that is larger than 10.5 (26,28). This electrostatic
ﬁeld provides nonspeciﬁc electrostatic interactions between
the enzyme and membrane surface that consequently enhance
binding to the anionic surface (1,16,18,27,29). Conversely,
other sPLA2 types, such as those isolated from snake venom,
lack the large number of cationic residues found in sPLA2-
IIA (1,20). These species are able to bind and hydrolyze both
zwitterionic and anionic lipid membranes, and do not exhibit
the surface charge speciﬁcity of sPLA2-IIA (20,30). The
ability of snake venom sPLA2 to also hydrolyze zwitterionic
membranes has been connected to the presence of aromatic
residues in the membrane putative interfacial binding surface
(31). These aromatic residues are essential for the nonpolar
interaction with the zwitterionic membrane (24,32), and they
may interact with membranes in distinct modes that deter-
mine membrane-binding afﬁnities and hence catalytic efﬁ-
ciency (32,33).
Members of the group II sPLA2s have drawn increased
attention, since these enzymes have been associated with a
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wide variety of immune-mediated inﬂammatory pathologies
in humans, ranging from systemic and acute inﬂammatory
conditions to cancer (9,28,34–39). For instance, high levels
of sPLA2 are associated with the onset of rheumatoid
arthritis (40,41), allergic rhitinis (42,43), and septic shock
(44,45). More recently, it was suggested that sPLA2-IIA has
a central role in both tumor development and progression
(46–49), since sPLA2-IIA occurs at elevated levels in cancer
tissue. This observation provides an avenue for site-speciﬁc
drug delivery by liposomal carriers, where the liposomes are
degraded speciﬁcally in the tumor tissue by sPLA2 releasing
antitumor drugs at the target site (48–50). Additionally, the
fatty acid and lysophospholipid hydrolysis products gener-
ated by sPLA2 have been shown to display a synergistic
effect as permeability enhancers for drug transport (2,48).
To further investigate the viability of using sPLA2-IIA as a
trigger of targeted drug delivery systems, we are interested in
new phospholipids with functionality in the sn-1 position.
These lipid molecules should be hydrolyzed effectively by
sPLA2-IIA and potentially serve as prodrugs. We demon-
strated earlier that a relatively small hydrophobic side chain
located at the sn-1 position is efﬁciently hydrolyzed by
sPLA2-IIA (51).
The aim of this study was to explore further which type of
side group (small versus bulky groups, hydrophobic versus
polar) can be introduced at the sn-1 position of the glycerol
backbone of glycerophospholipids. The insight gained from
this study is essential for determining the structural criteria
that allow sPLA2 to accommodate and tolerate phospholipids
with sn-1 substitutions. Furthermore, this knowledge pro-
vides the basis for using the sn-1 position as a possible
anchor point for drug conjugates or ﬂuorescence probes. The
latter can be used to probe interfacial properties of membranes.
We have chosen an interdisciplinary approach that combines
organic synthesis, biophysical characterization, and computer
simulations to obtain a detailed understanding of structural
properties in the substrate that determine sPLA2 activity. Here,
we report the results of our biophysical and computational
studies. The biophysical characterization was performed to
determine whether the modiﬁed lipids can form multilamellar
vesicles (MLVs) and be hydrolyzed by sPLA2. The experi-
mentally determined sPLA2 activities toward the different
phospholipids vary signiﬁcantly and strongly depend on the
type of substitution at the sn-1 position. These results were
further supported by computer simulations that provide further
insight into substrate recognition on a molecular level. Our
results generally indicate that, independent of the polarity of
the group substituted at the sn-1 position, limited space is
available in the binding cleft of sPLA2. We could identify two
essential contributions that may explain (in part) the difference
in the experimentally observed sPLA2 activities against the
synthesized substrates. First, speciﬁc lipid-protein interactions
impair the catalytic reaction; and second, steric hindrance
interferes with an incoming water molecule that acts as a
nucleophile in the enzymatic reaction.
METHODS
Preparation of vesicles
Phospholipids were hydrated in an aqueous buffer (150 mM KCl, 10 mM
HEPES, 30 mM CaCl2, 10 mM EDTA, pH ¼ 7.5). MLVs formed
spontaneously. To ensure complete hydration, the lipids were hydrated for
1 h at 65C. During the hydration, the lipids were vortexed every 15 min.
When small unilamellar vesicles (SUVs) were needed, the MLVs were
sonicated for 1 h at 5C above the lipid main-phase transition temperature.
The total concentration of lipids in the buffer solutions was 2 mM.
Differential scanning calorimetry (DSC) and
dynamic light scattering (DLS)
Differential scanning calorimetry (DSC) of 2 mM MLVs was performed by
using a Microcal MC-2 (Northhampton, MA) ultrasensitive power com-
pensating scanning calorimeter equipped with a nanovoltmeter. The scans
were performed in the upscan mode at a scan rate of 10C/h. An appropriate
baseline was subtracted from the calorimeter curves to afford the melting
enthalpies of the MLVs. Dynamic light scattering of the SUVs was
performed on a Zetasizer Nano particle analyzer (ZS ZEN3600, Malvern
Instruments, Westborough, MA).
Activity measurements
The conditions used to perform the sPLA2 activity measurements were as
follows: 0.15 mM phospholipid as SUVs, 150 nM sPLA2, 0.15 M KCl, 30
mM CaCl2, 10 mM EDTA, 10 mM HEPES (pH 7.5). The catalytic reaction
was initiated by addition of 8.9 mL of a 42-mM Agkistrodon piscivorus
piscivorus snake venom sPLA2 stock solution to a 2.5-mL SUV suspension
thermostated at the main phase-transition temperature of the vesicles before
the addition of the enzyme. The time-dependent activity of sPLA2 was
monitored from the changes in the 90 static light scattering giving
information of changes in the lipid morphology as non-bilayer-forming
lysophopholipids and fatty acids are generated. High-performance liquid
chromatography (HPLC) quantiﬁcation of the products from the enzymatic
reaction was performed with a 5-mm diol column. Two different mobile
phases (hereafter referred to as mobile phase A and mobile phase B) were
used. Mobile phase A was a chloroform/methanol/25% ammonium hydrox-
ide (800:195:5) solution, whereas mobile phase B was a chloroform/
methanol/water/25% ammonium hydroxide (600:340:50:5) solution. The
following gradients were used at a ﬂow rate of 1 mL/min: 0–14 min, 100%A
to 100% B using a linear gradient; 14–25 min, 100% B; 25–30 min, 100% B
to 100% A using a linear gradient; 30–45 min, 100% A to regenerate. An
evaporative light scattering detector was used for detection. Samples were
collected at different time intervals by collecting 100 mL of the reaction
mixture and rapidly mixing with a 0.5-mL chloroform/methanol/acetic acid
(2:4:1) solution to quench the reaction. The solution was washed with 0.5
mL of water, and 50 mL of the organic phase was used for HPLC. Fluo-
rescence measurements were performed using a DMX-1100 spectroﬂuo-
rometer (SLM, Urbana, IL). Puriﬁed snake venom PLA2 was a generous gift
from Dr. R. L. Biltonen (University of Virginia, Charlottesville, VA).
Molecular dynamics simulations
The crystal structures of European honeybee (Apis Mellifera) venoms sPLA2
complexed with the transition-state analog, 1-O-octyl-2-heptylphosphonyl-
sn-glycero-3-phosphoethanolamine (diC8(2Ph)PE), resolved to 2.0 A˚
(15,52) and human PLA2-IIA complexed with 6-phenyl-4(R)-(7-phenyl-
heptanoylamino)-hexanoic acid and resolved to 2.1 A˚ (53) were obtained
from the Protein Data Bank (entry codes 1poc and 1kqu, respectively) (54).
The initial modeling step involved placing diC8(2Ph)PE into the binding
cleft of hPLA2-IIA, which was done by 1), deleting the inhibitor in 1kqu
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(keeping the two calcium ions and water molecules in the structure); 2),
deleting calcium ions and water molecules in 1poc; 3), aligning 1poc with
1kqu; and, ﬁnally, 4) deleting the European honeybee venom PLA2
structure. The structures for the different phospholipids (Fig. 1) were built
from diC8(2Ph)PE using SPARTAN Version 1.0.2 (Wavefunction, Irvine,
CA). The modiﬁed lipids were introduced in the protein structures by
aligning the modiﬁed phospholipids with diC8(2Ph)PE in the enzyme-
diC8(2Ph)PE structures and subsequently deleting diC8(2Ph)PE. Missing
distance, angle, and torsion parameters for the sn-1 side chains were
obtained from the CHARMM27 parameter set (55) describing similar atom
types. The structures were solvated using the program SOLVATE (56).
Eighteen water molecules were randomly replaced with chloride ions to
neutralize the systems. The ﬁnal systems contained;4900 water molecules,
and the simulation cell dimensions were 52.7 3 51.7 3 67.3 A˚3. For the
molecular dynamics (MD) simulations, the software NAMD (57) was used
with the Charmm27 all-hydrogens parameter set and with the TIP3 water
model (55). Each complex was simulated at least three times starting from
different initial conditions, which were obtained by different steps of energy
minimization. The ﬁrst energy minimization of the systems involved 1000
steps. For each subsequent simulation of a certain complex, the number of
steps for energy minimization was increased by 250; that is, 1000, 1250, and
1500 steps were used for simulations of a complex that was repeated three
times. The minimization procedure was followed by 100 ps of heating of the
systems to 300 K. Each simulation was carried out for 10 ns in the NPT
ensemble. A time step of 1 fs was used throughout all simulations. An
isotropic constant ambient pressure of 1 atm was imposed using the
Langevin piston method (58) with a damping coefﬁcient of 5 ps1, a piston
period of 200 fs, and a decay of 500 fs. The particle mesh Ewald method was
used for computation of the electrostatic forces (59,60). The grid spacing
applied was;1.0 A˚, and a fourth-order spline was used for the interpolation.
The long-range part of the electrostatic forces was evaluated every fourth
femtosecond. The van der Waals interactions were cut off at 12 A˚ using a
switching function starting at 10 A˚. Periodic boundary conditions were
applied in x, y, and z directions. Examinations of the molecular structures
and analyses of the trajectories were carried out using tcl-scripting within the
graphical program Visualization Molecular Dynamics (61).
RESULTS AND DISCUSSION
The ability of secretory phospholipase A2 to hydrolyze a
broad range of phospholipid analogs has been explored in
developing new drug delivery systems (48,50). We previ-
ously demonstrated that sPLA2 can hydrolyze phospholipids
with their headgroup in the sn-2 position and phospholipids
with small substitutions in the sn-1 position (51,62). It is
intriguing that sPLA2 is able to hydrolyze phospholipids
with substitutions in the sn-1 position, since there is only
limited space available in the binding cleft of sPLA2. To
understand the structural restrictions for substitutions in the
sn-1 position at a molecular level, we present results that are
based on biophysical characterization of phospholipids and
computer simulation of sPLA2-phospholipid analog com-
plexes. The biophysical characterizations were performed to
ensure that the phospholipid analogs formed vesicles and
were hydrolyzed by sPLA2, whereas computer simulations
were carried out to provide structural insight on an atomic
level. We studied phospholipid analogs with sn-1 substitutes
having different properties, i.e., the side chains have different
size (bulkiness) and polarity. The chemical structures of the
synthesized compounds are shown in Fig. 1, and the phos-
pholipids contain hydroxy (compound A) methoxy (com-
pound B), benzyloxy (compound C), allyl (compounds D
and E), and ester (compounds F–H) groups. All compounds
except compound B were synthesized, and all compounds
were investigated in the computational study. The results
obtained from simulations of sPLA2 in complex with its
natural substrate (63) (hereafter referred to as ‘‘native’’) are
also included in the following discussion as a reference to the
phospholipid analogs.
Differential scanning calorimetry
DSC scans were performed to verify that the phospholipid
analogs formed MLVs and to ensure that the vesicles used in
the activity measurement assay were at the main phase
transition. All tested compounds showed a single peak in the
thermograph with a main phase transition above 35C.
However, T1/2, which is a measure of the cooperativity of the
phase transition, varies between the compounds (Table 1).
For compounds C and E, T1/2 , 1C, whereas for com-
pounds A, D, and F–H, T1/2 . 1C, with relatively broad
tails indicating that this series of compounds may not form
structural homogeneous MLVs. In particular, compounds A
(T1/2  3.7C) and F (T1/2  3.0C) have relatively broad
main phase-transition peaks, where the phase-transition
enthalpy (DH) for compound F is approximately half the
FIGURE 1 Chemical structure of compounds A–H.
TABLE 1 Differential calorimetry data of MLVs in the main
phase transition for compounds A and C–H
Compound DH (kJ/mole) Tm (C) T½ (C)
A 7.3 57.0 3.65
C 11.6 43.9 0.43
D 10.3 46.9 1.82
E 9.3 43.9 0.48
F 4.6 48.2 2.99
G 8.6 39.0 1.52
H 7.6 48.9 1.84
DH, melting enthalpy; T½, half-width; Tm, peak position.
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value observed for compounds C and E. These compounds
have comparable DH (9.3–11.6 kJ/mole) and the same Tm
(43.9C) (Table 1). Larger variations are observed for the
remaining phospholipid analogs. DSC of the SUVs showed
the usually observed broadening of the main phase transition
when MLVs are transformed into SUVs (64) (Fig. 2 D).
Dynamic light scattering measurements of the different
SUVs showed that the SUVs had an average diameter of
40–70 nm.
Activity measurements
We used 90 light scattering to qualitatively determine sPLA2
activity toward the different compounds. This approach is
only an indirect indication for sPLA2 activity, since it detects
the morphology changes of the liposomes. These changes
cannot be induced by the adsorption of the enzyme to the
liposome surface, since the concentration of sPLA2 is
signiﬁcantly lower than the concentration of the liposomes.
Hence, observed ﬂuorescence changes are induced by
hydrolysis. In this assay, SUVs consisting of compounds C,
E, and G showed no effect upon sPLA2 addition, whereas
morphology changes were detected for SUVs composed of
compounds A, D, F, and H (Table 2). Fig. 2 A shows a typical
appearance of a ﬂuorescence measurement that is represen-
tative for SUVs composed of compounds A, D, F, or H
(sPLA2 was added at 500 s to secure full equilibration of the
systems). The lower curve monitoring the morphology
changes of the system shows a period without any changes
in the system followed by a sudden increase (‘‘burst’’) in
ﬂuorescence, indicating the breakdown of the SUVs due to
sPLA2 hydrolysis.
FIGURE 2 The typical appearance of a ﬂuorescence
measurement on (A) SUVs composed of phospholipids
that are fairly good substrates for sPLA2, and (B) SUVs
composed of phospholipids that are poor substrates for
sPLA2. The upper lines show the intrinsic ﬂuorescence
from the enzyme, whereas the lower lines show the
morphology changes of the systems. (C) Typical HPLC
chromatogram illustrating the effect of sPLA2-catalyzed
hydrolysis of a phospholipid from SUVs that is a fairly
good substrate. The chromatograms show the amount of
phospholipid before the addition of sPLA2 (solid line) and
1000 s (dashed line) and 6000 s (dotted line) after the
addition of sPLA2. (D) Typical DSC scans for MLVs and
SUVs. Scans are representative of all phospholipids
studied.
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The intrinsic ﬂuorescence from tryptophan in the enzyme
shows a sudden sharp increase after addition of sPLA2 (Fig.
2 A, upper curve), which might be a result of sPLA2 imme-
diately attaching to the surface of the negatively charged
vesicles. During the experiment, the intrinsic ﬂuorescence
decreases, which is expected, since sPLA2 hydrolysis leads
to the breakdown of SUVs, and consequently results in small
aggregates to which sPLA2 binds less efﬁciently. Fig. 2 B
shows a typical appearance of the ﬂuorescence measure-
ments representative for SUVs composed of compounds C,
E, or G. No morphology changes of the systems (lower
curve) are observed, indicating that these compounds are
poor substrates for sPLA2. Furthermore, the intrinsic ﬂuo-
rescence from tryptophan of the enzyme (upper curve)
shows no signiﬁcant change after the addition of the enzyme.
Again, the initial sharp increase might be a sign of instan-
taneous sPLA2 attachment to the surface of the SUVs. The
ﬂuorescence measurements were followed by HPLC studies
to demonstrate the link between morphology changes and
sPLA2 activity. Fig. 2 C shows an example of a typical HPLC
measurement on systems in which ﬂuorescence measure-
ments indicate morphology changes. A substantial decrease
in the amount of phospholipid in the sample before addition
of sPLA2 (solid line) and 1000 s (dashed line) and 6000 s
(dotted line) after addition of the enzyme is observed.
Clearly, HPLC results conﬁrm that the indirectly observed
morphology changes are induced by sPLA2 hydrolysis of the
phospholipids in the SUVs. The results obtained from the
ﬂuorescence measurements and the HPLC studies on
compounds A and C–H are summarized in Table 2.
MD simulations
The biophysical characterization revealed that although the
tested phospholipids can form MLVs, only some of the phos-
pholipid analogs are relatively good substrates for sPLA2. To
understand, on a structural level, the observed different
sPLA2 activity toward the phospholipids, we applied com-
putational methods. Initially, we applied simple docking of
the phospholipid analogs to sPLA2. These results were not
conclusive, and they indicated that all phospholipids ﬁt into
the binding cleft of sPLA2. We therefore applied MD
simulations (65,66) to gain further insight into the mecha-
nism(s) that could explain the experimentally observed
activities. Enzymatic reaction depends on several factors,
including binding of the enzyme to the membrane surface,
membrane properties, formation of the Michaelis-Menten
complex, etc. (18,66,67). Here, we only consider one step in
the process, and have conﬁned ourselves to a study, using
classical mechanics, of the dynamics of substrate binding
before the formation of the transition state. Our approach was
motivated by the work of, e.g., Cho and co-workers (68) and
Menger (69), who have challenged the classical hypothesis
(70) that enzyme catalysis can only be improved by further
stabilizing the transition state. The authors demonstrated
that it may be at least as advantageous to consider ways of
engineering the substrate, which could improve substrate
binding, and/or product clearance (removal of product inhi-
bition effects) (68–74).
It is well established that membrane properties affect
enzyme activity (19), and that binding of some sPLA2 spe-
cies to the membrane surface is governed by the interfacial
charge distribution of the membrane (19,20,63). For in-
stance, snake venom sPLA2 can hydrolyze both membranes
consisting of zwitterionic phosphatidylcholine and those
consisting of negatively charged phosphatidylglycerol (PG)
phospholipids, whereas human sPLA2-IIA shows only activ-
ity toward membranes containing PG (1,16,19,24,27,29). This
has been correlated to the binding surface of the enzyme.
sPLA2-IIA has a relatively high positively charged binding
surface (i-face) that makes critical contacts to negatively
charged phospholipids (23,75). However, once bound to the
surface, sPLA2-IIA can hydrolyze phosphocholine and PG
phospholipids (20), indicating a more generic catalytic
mechanism, which is not strongly dependent on the head-
group. Hence, it is expected that the results obtained in this
study are relevant for snake venom sPLA2 as well as for
human sPLA2-IIA. The series of compounds used in this
study is only modiﬁed in the sn-1 position of PG, which
FIGURE 3 Schematic representation of the catalytic mechanism of sPLA2
and key interactions that stabilize the Michaelis-Menten complex. Atom
types given in parentheses refer to the Protein Data Bank nomenclature.
TABLE 2 Overview of the results obtained from ﬂuorescence
measurements and HPLC studies for compounds A and C–H
Compound
Morphology changes observed
by ﬂuorescence
Activity observed
by HPLC
A 1 1
C  
D 1 1
E  
F 1 1
G  
H 1 1
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means that measuring no activity cannot be due to the lack of
binding of sPLA2 to the membrane surface, but has to be
related to the catalytic reaction.
The catalytic mechanism of sPLA2 is schematically shown
in Fig. 3, where the numbering corresponds to the numbering
used for sPLA2-IIA. The catalytic site consists essentially of
four components: a histidine (His47), an aspartate (Asp91), a
calcium ion (cofactor), and a water molecule that acts as the
nucleophile (15,76). The catalytic reaction is initiated by
forming a Michaelis-Menten complex between the substrate
and sPLA2. The complex is stabilized by Ca
21 that coor-
dinates to the substrate via the carbonyl oxygen (O22) and
phosphonate oxygen (O4), as well as to the protein via the
backbone oxygen of Gly29 (O) and the two carboxylate
oxygens of Asp48 (OD1 and OD2) (Fig. 4). Additionally,
Lys62, which is highly conserved in the group II sPLA25,
interacts with the sn-3 phosphate oxygen (1,77), thereby
contributing to the stabilization of the complex (1,77). The
reactive carbonyl carbon atom of the ester bond (Fig. 3, C21)
is then attacked by a nucleophilic water molecule, leading to
the formation of a tetrahedral intermediate (close to the tran-
sition state), which is stabilized by the backbone hydrogen of
the NH group of Gly29 (oxyanion hole) and the calcium ion
(15,76,78). During the formation of the intermediate phase,
the hydrogen atom of the water molecule is transferred to
His47, and thereby, the histidine imidazole ring becomes
positively charged. The protonated His47 is stabilized by
Asp91, which hydrogen-bonds to Tyr51 and Tyr66 (Fig. 3).
The proton abstracted from His47 is ideally positioned to
protonate the sn-2 oxygen in concert with the productive
collapse of the tetrahedral intermediate (3,15,79). Molecular
dynamics simulation is a classical approach that cannot ac-
count for transition state or processes involving bond breaking
(66,71). We therefore focused on the Michaelis-Menten com-
plex of the different compounds. One of the requirements for
catalysis is that a stable complex can be formed and that the
key distances (involving the Michaelis-Menten complex) are
maintained. We have used these criteria to study the stability
of the different complexes and to investigate whether that
stability can be correlated to the observed sPLA2 activity
toward the different compounds.
MD—protein stability
Simulations were performed at least three times for each
complex, to verify the signiﬁcance of the results (Table 3).
For each simulation, the root mean-square deviation
(RMSD) of Ca atoms with respect to the protein structure
TABLE 3 Summary of the simulations
Compound
Number of
simulations
Length of
simulations (ns)
Root mean-square
deviation mean 6 SD (A˚)
A 3 each 10 1.5 6 0.1
B 3 each 10 1.4 6 0.1
C 3 each 10 1.4 6 0.1
D 3 each 10 1.7 6 0.1
E 4 each 10 1.3 6 0.1
F 3 each 10 1.2 6 0.1
G 4 each 10 1.5 6 0.1
H 3 each 10 1.4 6 0.1
native 6 each 10 1.3 6 0.1
The last column lists the average RMSD of Ca atoms with respect to the
protein structure after minimization. Means and their standard deviations
(SD) are based on a series of simulations of a particular complex:
SD ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
+N
i¼1ðxixÞ2
N1
q
: ‘‘Native’’ refers to the natural substrate of sPLA2 ((R)-
1,2-dipalmitoyl-glycero-3-phosphocholine) (63).
FIGURE 4 RMSDs of Ca atoms with respect to
the initial sPLA2 structure as a function of simula-
tion time. (Inset) Comparison of the average residue
ﬂuctuations based on Ca atoms and averaged over
the last 5 ns of the simulation (—) with the
RMSD derived from the crystallograhic Bfactor:
RMSD ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃBfactor3 3=ð8p2Þ
p
(–) (53,89). The
data were extracted from a simulation of sPLA2 in
complex with compound D and are representative
for all simulations.
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after minimization was calculated as a function of time to
check the stability of the simulation. In Fig. 4, the time
evolution of RMSD extracted from an sPLA2-compound D
simulation is shown as an example. RMSD approaches a
constant value of ;1.7 A˚ within 3 ns. Similar results were
obtained for the other simulations, and the average RMSDs
calculated from the different simulations are summarized in
Table 3. Variations are within the statistical uncertainties and
the overall RMSD averaged over all RMSDs is 1.56 0.1 A˚.
We also compared the ﬂuctuations of Ca atoms with the
crystallographically determined B-factors (53) (Fig. 4, inset).
The ﬂuctuations extracted from simulations resemble the
B-factor, but have larger magnitudes in loop regions that are
exposed to solvent. These deviations are not surprising, since
these regions may be affected by crystal packing (71,80).
MD—key distances
For the catalytic reaction to occur, a stable Michaelis-Menten
complex has to form, which implies that distances stabilizing
the complex are maintained (65,81). We therefore monitored
distances involving the cofactor calcium (Ca21 to Asp48(OD1),
Asp48(OD2), Gly29(O), S(O22), S(O4) (Fig. 5, where atom
types and S refer to the Protein Data Bank nomenclature and
substrate, respectively) or residues in the vicinity of the
substrate (Asp91(OD1)-Tyr51(OH), Asp91(OD2)-Tyr66(OH),
FIGURE 6 Time evolution of selected distances be-
tween atoms that are close to the substrate. Distances are
given in the individual panels. See Fig. 5 legend for more
details.
FIGURE 5 Time evolution of selected distances involv-
ing the cofactor calcium. Distances are given in the indi-
vidual panels (A–D). S, substrate; atom types correspond to
Protein Data Bank nomenclature (see also Fig. 4). The
distances were extracted from a simulation of sPLA2 in
complex with compound D and are representative for all
simulations.
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His47(ND1)-S(C21), His47(HE2)-Asp91(OD1), and Gly29(O)-
S(O22) (Fig. 6)). The data were extracted from an sPLA2-
compound D simulation, and similar results were observed in
all other simulations. To compare those, we have calculated
mean distances for each complex averaged over time (the last 5
ns of the simulations) and over simulations of that complex.
The average distances are listed in Table 4. For reference, the
results for the sPLA2-native simulations are also included in
the last column of Table 4. Distances extracted from simula-
tions of different sPLA2-phospholipid complexes are within
the statistical uncertainties and compare well to distances
determined from the sPLA2-native simulations. Exceptions are
particularly observed for distances Asp91–Tyr51 and Asp91–
Tyr66, which are ;1.2 A˚ shorter than those monitored in the
sPLA2-native complex, indicating structural effects caused by
the sn-1 substitute. The two tyrosines are not required to
maintain activity, since mutants in which these two residues
were mutated to phenylalanine had virtually unaltered catalytic
performance (78). For the single mutant Asp/Asn, signiﬁ-
cant catalytic activity was retained. Both observations suggest
that the hydrogen-bonding network plays only a minor role for
the catalytic turnover. Variations in distance are also observed
for His47(ND1)-S(C21) and S(O22)-Gly29(HN) in the different
complexes. However, as shown in Fig. 7, these variations are
within the statistical uncertainty when compared to the native
phospholipid, and hence, we cannot attribute the lack of sPLA2
activity toward some of the phospholipid analogs to these
variations.
MD—nucleophilic water molecule
We previously showed that for phospholipid analogs with
their headgroup located in the sn-2 position, the enzymatic
reaction is affected by the probability that a water molecule
can reach the catalytic site (63). We speculated that a similar
effect could be the reason for our observations in this study.
We therefore monitored the movements of water molecules
and registered when a water molecule reached the vicinity of
His47(ND1) and S(C21) (Fig. 3) (63). These two residues
will hereafter be referred to as H-S. An example of a water
molecule trajectory monitored in an sPLA2-native simulation
is shown in Fig. 8 A. Fig. 8 B displays images taken from the
trajectory at different time intervals (t1 , t2 , t3) and shows
the entering of a water molecule into the H-S region. From
the data, we calculated the probability of water molecules
being at a certain distance from H-S; the average relative
water counts extracted from the simulations are shown in
Fig. 9, and the data are provided in Table 5. There are
signiﬁcant differences and the probability of observing a
water molecule at a certain distance from H-S depends on the
compound. Within the time interval of the simulations, water
molecules within 3.5 A˚ of H-S could be detected for
FIGURE 7 Average distances of His47(ND1)-S(C21) and S(O22)-
Gly29(HN) extracted from the simulations of the different sPLA2-phospho-
lipid complexes. Averages were calculated from a series of simulations of a
particular complex, and only the last 5 ns of each simulation was used in the
calculations. Dashed and dotted lines indicate the upper and lower error,
based on the native substrate for His47(ND1)-S(C21) and S(O22)-Gly29(HN)),
respectively. See Fig. 5 legend for more details.
TABLE 4 Summary of the calculated distances between selected atoms that are involved in stabilization of the substrate or part
of the catalytic device
Compound A B C D E F G H Native
Distances Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
Mean 6 SD
(A˚)
D91(OD1)–Y51(OH) 1.7 6 0.2 1.7 6 0.1 1.8 6 0.2 1.8 6 0.2 1.7 6 0.1 1.7 6 0.1 1.7 6 0.1 1.7 6 0.1 3.1 6 0.3
D91(OD2)–Y66(OH) 1.7 6 0.1 1.7 6 0.1 1.7 6 0.2 1.7 6 0.1 1.7 6 0.1 1.7 6 0.1 1.7 6 0.1 1.7 6 0.1 2.7 6 0.1
H47(HE2)–D91(OD1) 1.9 6 0.2 1.9 6 0.1 1.8 6 0.2 1.8 6 0.1 1.8 6 0.2 1.9 6 0.2 1.9 6 0.2 1.9 6 0.3 1.9 6 0.3
H47(ND1)–S(C21) 5.2 6 0.4 4.4 6 0.3 4.5 6 0.4 4.2 6 0.3 4.8 6 0.2 4.1 6 0.4 4.8 6 0.2 4.8 6 0.4 4.5 6 0.4
Ca21–D48(OD1) 2.2 6 0.1 2.2 6 0.1 2.2 6 0.1 2.2 6 0.1 2.3 6 0.3 2.2 6 0.1 2.2 6 0.1 2.2 6 0.1 2.2 6 0.2
Ca21–D48(OD2) 2.4 6 0.3 2.3 6 0.2 2.3 6 0.1 2.2 6 0.1 2.5 6 0.3 2.2 6 0.1 2.2 6 0.1 2.2 6 0.1 2.2 6 0.1
Ca21–G29(O) 2.3 6 0.1 2.3 6 0.1 2.3 6 0.1 2.4 6 0.1 2.9 6 0.3 2.3 6 0.1 2.3 6 0.1 2.3 6 0.1 2.4 6 0.2
S(O22)–G29(HN) 3.8 6 0.9 3.0 6 0.5 3.0 6 0.5 3.6 6 0.8 3.4 6 0.7 2.6 6 0.4 3.1 6 0.5 2.6 6 0.4 2.7 6 0.5
S(O22)–Ca21 2.9 6 0.5 2.4 6 0.2 2.3 6 0.2 2.3 6 0.1 2.3 6 0.1 2.4 6 0.1 2.3 6 0.1 2.3 6 0.1 2.4 6 0.2
S(O4)–Ca21 2.1 6 0.1 2.1 6 0.1 2.1 6 0.1 2.1 6 0.1 2.1 6 0.1 2.1 6 0.1 2.1 6 0.1 2.1 6 0.1 2.1 6 0.1
See Scott et al. (15) and Janssen et al. (76). Protein Data Bank nomenclature (see also Fig. 4) has been used for atom types. See Table 3 note for more details.
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compounds A, D, E, G, and the natural substrate. Water
molecules within 4.5 A˚ of H-S could be observed for
compounds B, F, and H, whereas no water molecules could
be observed for compound C within this range. These
ﬁndings relate partly to the observed sPLA2 activity, where
we found that compounds A, D, F, and H serve as fairly good
substrates for sPLA2. Our simulation results would suggest
that compounds A, D, E, and G are relatively good substrates
for sPLA2, whereas compounds B, F, and H are less
efﬁciently hydrolyzed by sPLA2. Based on the relative water
count, the activity can be ranked as follows: natural substrate
 A. G E. D. H F B. Besides compounds E and
G, our ﬁndings agree well with the experimental data. To
further elucidate the discrepancy observed for compounds E
and G, we have followed the trajectories of water molecules
and analyzed with which residues/atoms the water molecules
interact as they approach H-S.
MD—key structural interference
Despite the relatively high water count for compounds E and
G, these phospholipid analogs are not hydrolyzed by sPLA2.
Further analysis of the water trajectories provided additional
information about the effect of the sn-1 side chain on the
hydrolysis. The simulation revealed that the two methyl
groups located at the ﬁrst carbon of the sn-1 side chain cause
steric hindrance such that water molecules cannot freely
reach the H-S site. Fig. 10 displays snapshots of the active
site of sPLA2 taken from sPLA2-compound D, sPLA2-
compound E, and sPLA2-compound G simulations. The
image taken from the sPLA2-compound D simulation is
included as a reference. This compound is a relatively good
substrate for sPLA2 and, as shown in Fig. 10, a water
molecule can freely approach the H-S region. In contrast, for
compounds E and G (Fig. 10, conﬁguration 1), a water
molecule can only be detected in the vicinity of His47 and
cannot reach the H-S region. A methyl group located at the
ﬁrst carbon of the sn-1 chain blocks the water molecule from
approaching the correct position (i.e., H-S region) such that it
can act as the nucleophile in the enzymatic reaction.
Furthermore, His47 cannot perfectly align in the dyad, due
to the bulkiness of the methyl group. For compound G, a
second conﬁguration is observed where the carbonyl oxygen
of the ester group coordinates to a water molecule that has
entered the H-S region (Fig. 10, conﬁguration 2). Here,
strong coordination of the water molecule by the ester group
prevents activation of the water molecule for the nucleophilic
attack.
FIGURE 8 (A) Trajectory of a water molecule moni-
tored in an sPLA2-Native simulation. Distances are
calculated with respect to the substrate S(C21) (upper)
and His47(ND1) (lower). (B) Snapshots taken from the
trajectory displayed in A. Images are taken at different time
intervals (t1 , t2 , t3) and show the entrance of a water
molecule into the H-S region. Note that, for clarity, only
the water molecule that is entering the H-S region is
shown.
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CONCLUSION
We used biophysical techniques and MD simulations to
understand, on a molecular level, the structural restrictions
for substitutions in the sn-1 position. We studied phospho-
lipid analogs with sn-1 substitutes of different properties,
where size (i.e., bulkiness) and polarity are varied (Fig. 1).
The biophysical characterization revealed that all phospho-
lipid analogs form MLVs, but only compounds A, D, F, and
H are potential good substrates for sPLA2.
Molecular dynamics simulations provided structural insight
on an atomic level. Notwithstanding the clearly demonstrated
importance of transition state studies (82–88), we suggest that
the steps before the transition state can also critically deter-
mine the outcome of the reaction. Our simulations revealed
that the difference observed in sPLA2 activity is caused by
less efﬁcient access of water molecules to the active site. We
monitored the number of water molecules that enter the region
between His47(ND1) and S(C21) (Fig. 3) for the different
sPLA2-phospholipid complexes and found that the probabil-
ity of a water molecule reaching the correct position such that
hydrolysis can occur varies among the different phospholipid
analogs. Based on the relative water count, the activity can be
ranked as follows: natural substrate . A . D . H  F. In
agreement with experimental results, sPLA2 shows no activity
toward compounds E and G, since the methyl group located at
the ﬁrst carbon of the sn-1 substitute (compound E) or the
TABLE 5 Relative water count extracted from the
different simulations
Compound
Relative water
count at 3.5 A˚
(mean 6 SD)
Relative water
count at 4.5 A˚
(mean 6 SD)
Relative water
count at 5.5 A˚
(mean 6 SD)
A 0.02 6 0.02 0.4 6 0.3 0.6 6 0.2
B 0 0.002 6 0.003 0.3 6 0.2
C 0 0 0.0002 6 0.0005
D 0.0002 6 0.0003 0.2 6 0.3 0.6 6 0.5
E 0.01 6 0.02 0.2 6 0.3 0.4 6 0.3
F 0 0.004 6 0.007 0.2 6 0.3
G 0.1 6 0.1 0.2 6 0.3 0.3 6 0.3
H 0 0.01 6 0.02 0.3 6 0.4
Native 0.1 6 0.1 0.4 6 0.2 0.7 6 0.1
Before calculating the averages, the data were arbitrarily normalized by the
water count at 6 A˚, since there were signiﬁcant differences in the water
count within a series of simulations of a particular complex. See Table 3
note for more details.
FIGURE 10 Snapshots of the active site of sPLA2 taken from sPLA2-
compound D, sPLA2-compound E, and sPLA2-compound G simulations.
Secondary protein structure of the enzyme is shown in the ribbon mode.
His48, the substrate, and a water molecule are shown in the liquorice and are
colored according to atom type (H, white; N, blue; O, red; and P, gold). The
cofactor calcium is shown in van der Waals and is colored blue.
FIGURE 9 Relative water count extracted from the different simulations
and averaged over a series of simulations of a particular complex. Before
calculating the averages, the data extracted from each simulation were
arbitrarily normalized by the water count at 6 A˚. The numbers given in the
graph belong to the third column and represent the ratio of the relative water
count at 4.5 A˚ to the relative water count at 5.5 A˚.
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ester group (compound G) blocks water molecules from
reaching the right position that would allow hydrolysis. The
future plan for this work is to use the MD simulations to
predict the ability of sPLA2 to hydrolyze a given substrate
with more complicated residues in the sn-1 position. Conse-
quently, our approach may be used in the design and devel-
opment of new phospholipids with anticancer drugs linked to
the sn-1 position.
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